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Abstract
Skeletal muscle is the major site for glucose disposal, the impairment of which closely asso-
ciates with the glucose intolerance in diabetic patients. Diabetes-related ankyrin repeat pro-
tein (DARP/Ankrd23) is a member of muscle ankyrin repeat proteins, whose expression is
enhanced in the skeletal muscle under diabetic conditions; however, its role in energy
metabolism remains poorly understood. Here we report a novel role of DARP in the regula-
tion of glucose homeostasis through modulating AMP-activated protein kinase (AMPK)
activity. DARP is highly preferentially expressed in skeletal muscle, and its expression was
substantially upregulated during myotube differentiation of C2C12 myoblasts. Interestingly,
DARP-/- mice demonstrated better glucose tolerance despite similar body weight, while
their insulin sensitivity did not differ from that in wildtype mice. We found that phosphoryla-
tion of AMPK, which mediates insulin-independent glucose uptake, in skeletal muscle was
significantly enhanced in DARP-/- mice compared to that in wildtype mice. Gene silencing
of DARP in C2C12 myotubes enhanced AMPK phosphorylation, whereas overexpression
of DARP in C2C12 myoblasts reduced it. Moreover, DARP-silencing increased glucose
uptake and oxidation in myotubes, which was abrogated by the treatment with AICAR, an
AMPK activator. Of note, improved glucose tolerance in DARP-/- mice was abolished when
mice were treated with AICAR. Mechanistically, gene silencing of DARP enhanced protein
expression of LKB1 that is a major upstream kinase for AMPK in myotubes in vitro and the
skeletal muscle in vivo. Together with the altered expression under diabetic conditions, our
data strongly suggest that DARP plays an important role in the regulation of glucose homeo-
stasis under physiological and pathological conditions, and thus DARP is a new therapeutic
target for the treatment of diabetes mellitus.
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Introduction
Diabetes has been prevalence worldwide, and its morbidity is increasing rapidly, especially in
developing countries [1]. Majority of diabetes is the type 2 diabetes that is closely associated
with obesity. The primary cause of type 2 diabetes is insufficient insulin action in the body.
Insulin targets various organs, but the principal insulin targets are liver, adipose tissue and skel-
etal muscle. Skeletal muscle accounts for ~75% of whole body insulin-mediated glucose uptake,
and muscle insulin resistance could account for over 85% of the impairment in glucose disposal
in type 2 diabetic subjects [2]. Therefore, improving muscle glucose uptake is a promising
approach for the treatment of diabetic patients.
Glucose is transported into the cells through insulin-dependent and insulin-independent
pathways. Upon insulin-stimulation, glucose transporter 4 (GLUT4) is translocated onto
plasma membrane to mediate insulin-dependent glucose disposal into skeletal muscle and adi-
pose tissue [3]. GLUT4 mediates insulin-independent glucose uptake as well, in response to
exercise through AMP-activated protein kinase (AMPK) pathway [3]. AMPK is an energy-
sensing enzyme that governs systemic energy metabolism, and is dysregulated in animals and
humans with metabolic syndromes and/or type 2 diabetes [4,5]. On the other hand, GLUT1 is
widely distributed in various tissues, and mediates constitutive, insulin-independent glucose
uptake [6].
We previously identified a nuclear protein, termed diabetes-related ankyrin repeat protein
(DARP; also known as CARP3 or ANKRD23), whose expression was differentially regulated in
obese and/or insulin-resistant subjects [7]. DARP belongs to muscle ankyrin repeat protein
(MARP) family that is considered to play a crucial role in the integration of cytoskeletal archi-
tecture, stress response and transcriptional regulation [8,9]. MARP family includes cardiac
ankyrin repeat protein (CARP) that is predominantly expressed in the heart, and ankyrin
repeat domain 2 (ANKRD2) that is widely expressed in many tissues with a high expression in
the skeletal muscle and heart [8,9]. DARP is highly and preferentially expressed in skeletal
muscle and its expression in skeletal muscle was enhanced in obese rats, while it was reduced
during fasting in lean mice [7]. These observations suggest a possible role of DARP in energy
metabolism, especially in skeletal muscle, but it remains largely unexplored. Here we investi-
gated a potential role of DARP in glucose homeostasis using DARP-deficient (DARP-/-) mice,
and found that loss of DARP enhanced systemic glucose tolerance without affecting insulin-
sensitivity by increasing AMPK activity in skeletal muscle.
Materials and Methods
Materials
AICAR was obtained fromWako Pure Chemical Industries. Antibodies for phospho-AMPKα
(Thr172) (40H9), total-AMPKα, phosphor-ACC (Ser79), total-ACC and LKB1 were obtained
from Cell Signaling Technology. GAPDH antibody was obtained fromMerck Millipore. Sec-
ondary antibodies for mouse IgG and rabbit IgG were obtained from Santa Cruz
Biotechnoligy.
siRNA for DARP was obtained from Dharmacon, and the negative control siRNA (scram-
ble) was obtained from Ambion.
Cell culture
C2C12 mouse skeletal myoblast cell line was cultured in DMEM supplemented with 10% fetal
bovine serum and 1% penicillin and streptomycin. Myogenesis was induced as described previ-
ously [10]. Briefly, when cells reached 70–80% confluency, the growth medium was switched
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to differentiation medium (DMEM supplemented with 2% horse serum and 1% penicillin and
streptomycin) to induce myogenesis. Differentiation medium was changed every other day
until cells well differentiate into myotubes (regularly for 5–9 days).
Gene-silencing of DARP
Differentiated C2C12 myotubes (3–5 days after giving differentiation medium) were trans-
fected with 50 nM siRNA for either DARP or scramble by using Lipofectamine RNAiMAX
(Invitrogen), according to the manufacturer's instructions. The fresh differentiation medium
was given after 24 h, and cells were incubated for another 48 h before use for experiments.
Overexpression of DARP
Preparation of retrovirus was performed as reported previously [11]. Briefly, cDNA for target-
ing gene (DARP-FLAG) was subcloned into pMSCVneo vector (Clontech). GP2-293 packag-
ing cells were transfected with DARP-pMSCVneo plasmid and pVSV-G plasmid (Clontech)
using Lipofectamine 3000. In a parallel way, GP2-293 cells were transfected with GFP-
pMSCVneo and pVSV-G plasmids to prepare viruses for negative control. Fresh growth
medium was replaced 24 h after transfection, and cells were incubated for another 24h, fol-
lowed by collection of the virus-containing culture medium. For infection, myoblasts of 50–
60% confluency were incubated in the mixture of growth medium and the virus-containing
culture medium at 1:1 ratio in the presence of 8 μg/ml polybrene for 24 h. Thereafter, cells
were given fresh medium and incubated for 24–48 h followed by protein extraction.
Animal study
All protocols for animal experiments were approved by the Ethics Review Committee for Ani-
mal Experimentation in Kyoto Prefectural University of Medicine. The total number of mice
used in this study is 72. Detailed method for the generation of DARP-deficient mice was
described previously [12]. Exon 1–3 of DARP gene were replaced by cDNA encoding LacZ and
a pGK neo cassette in the targeted allele.
DARP-/- and WTmice (C57BL6) were fed with normal chow (containing 23.1% protein
and 5.1% fat). For all the experiments using mice, mice were regularly anesthetized with iso-
flurane prior to every procedure to minimize suffering of the mice. When sacrifice the mice,
mice were anesthetized with isoflurane and then sacrified by cervical dislocation.
Treatment with AICAR in vivo
Treatment with AICAR in vivo was performed as described previously [13]. C57BL6 mice and
DARP-/- mice were given an intraperitoneal injection of AICAR (0.25 mg/g) for 5 days prior
to the ipGTT analysis. The condition of mice treated with AICAR was regularly monitored
every day.
Treatment with AICAR in vitro
Treatment with AICAR in vitro was performed as described previously [14]. Differentiated
C2C12 myotubes transfected with scramble or DARP siRNA were treated with AICAR at a
final concentration of 1 mM for 1 h, followed by protein extraction in RIPA buffer.
Immunoblotting
Cell or tissue lysates were prepared in RIPA buffer containing protease and phosphatase inhibi-
tors, and then immunoblotting was performed as described previously [15]. Lysates containing
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the same amount of proteins (~60 μg for culture cells and ~120 μg for quadriceps muscles)
were subjected to SDS—PAGE, followed by transferring onto the nitrocellulose membrane.
The membranes were blocked in 5% non-fat milk in TBS containing 0.05% tween20 at room
temperature for 1 h. Membranes were then incubated with specific antibodies for target mole-
cules. The dilution of primary antibodies was; phospho-AMPKα (1:1000), total-AMPKα
(1:1000), phospho-ACC (1:1000), total-ACC (1:1000), LKB1 (1:1000), GAPDH (1:2000) and
secondary antibodies for mouse IgG and rabbit IgG (1:4000).
Quantitative RT-PCR
Quantification of mRNA expression of target genes was performed as described previously
[16]. Total RNAs of skeletal muscle and C2C12 cells were isolated by using Trizol (Invitrogen),
followed by purification with NucleoSpin RNA Clean-up (MACHEREY-NAGEL). Comple-
mentary DNA was synthesized from 0.5–1 μg total RNA using PrimeScript RT Reagent kit
with gDNA Eraser (TaKaRa). PCR reactions were prepared by using KAPA SYBR FAST Mas-
ter Mix Universal (KAPA BIOSYSTEMS) followed by the real-time PCR using Thermal Cycler
Dice (TaKaRa). Nucleotide sequence of each primer is shown in Table 1. mRNA levels for tar-
get genes relative to 18S rRNA or actin was shown for all the experiments.
Metabolic measurement
The intraperitoneal glucose tolerance test (ipGTT) and insulin tolerance test (ITT) were per-
formed as reported previously [17]. Briefly, for the ipGTT, mice were fasted for 8 h by deplet-
ing chows in the morning, and subsequently D-glucose was intraperitoneally administrated at
the dose of 1.5 g/kg. Blood was collected at indicated time points, and blood glucose was mea-
sured by the glucose oxidase method (Sanwa Kagaku). For the ITT, mice in the absence of fast-
ing treatment were subcutaneously given human insulin at the dose of 1 U/kg. Blood was
collected at indicated time points, and blood glucose was measured. For quantitative analysis,
the are-under-curve for ipGTT and ITT was also calculated.
Measurement of glucose uptake in myotubes
Myotubes were serum-starved for 6 h and subsequently incubated with DMSO (control) or 2
mM AICAR for 15 min. Glucose uptake was determined by 2-deoxyglucose uptake with an
enzymatic photometric assay by using 2-deoxyglucose uptake measurement kit (COSMO BIO
Co. Ltd.) according to the manufacturer’s instructions.
Table 1. Nucleotide sequences of primers.
GLUT1-forward 5’-CAATGGCGGCGGTCCTATAA-3’
GLUT1-reverse 5’-GAGAGACCAAAGCGTGGTGA-3’
GLUT4-forward 5’-ACTCTTGCCACACAGGCTCT-3’
GLUT4-reverse 5’-CCTTGCCCTGTCAGGTATGT-3’
LKB1-forward 5’-GGCATGGACACCTTCATCCA-3’
LKB1-reverse 5’-TCCTTCTTGACGTTGGCCTC-3’
DARP-forward 5’-AGCTGCTATAGAAGTACGGGATTTGC-3’
DARP-reverse 5’-GGACACTCGATAAGGTGCTCTAGGCA-3’
ANKRD2-forward 5’-CCCTGTGAATGAGGAGACATTCCTG-3’
ANKRD2-reverse 5’-CCAGAAGTTTCTCCAGTATCTCCATGTG-3’
Actin-forward 5’-AGCCATGTACGTAGCCATCC-3’
Actin-reverse 5’-CTCTCAGCTGTGGTGGTGAA-3’
doi:10.1371/journal.pone.0138624.t001
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Measurement of (14C)-glucose oxidation in myotubes
Oxidation of glucose was assessed by measuring the production of 14CO2 from (
14C)-D-glucose
as described previously [18]. Briefly, myotubes transfected with either scramble or DARP
siRNA were incubated with serum- and glucose-depleted medium containing fatty acid-free
BSA and 5550 Bq/mL (14C)-D-glucose at a ratio of 1:2.5 in the presence or absence of AICAR
(2 mM). To measure conversion of (14C)-D-glucose into 14CO2, a piece of Whatman papers
wet with phenylethylamin/methanol (1:1) were taped onto the top of culture dish (35mm) to
trap the CO2 produced during the incubation period. After incubation for 2 h, 200 μl of H2SO4
(4 mol/l) was added to release all the 14CO2, and cells were further incubated for 1 h. Subse-
quently, the seal was removed, and the pieces of Whatman papers were carefully collected and
their radioactivities were measured by liquid scintillation counting.
Statistical analysis
All data are presented as mean±S.E. Differences between groups were analyzed by the Student’s
t-test or one-way ANOVA. P<0.05 was considered statistically significant.
Results
DARP is highly expressed in skeletal muscle and mature myotubes
We previously reported that DARP is highly expressed in the skeletal muscle, and modest
expression was detected in the heart and brown adipose tissue, assessed by northern blot analy-
sis [7]. Therefore, we quantitatively analyzed the mRNA expression of DARP in mouse tissues,
and found that DARP is expressed predominantly in skeletal muscle (Fig 1A). We then exam-
ined whether DARP expression is differentially regulated during myogenesis. C2C12 myoblasts
expressed DARP at considerably low level, and DARP expression was substantially increased
during myotube differentiation, indicating that DARP is predominantly expressed in mature
myotube (Fig 1B). We also investigated ANKRD2 expression during myogenesis. ANKRD2
showed the lesser degree of upregulation during myogenesis, and undifferentiated myoblasts
expressed ANKRD2 at a comparable level to mature myotubes (Fig 1B).
Genetic inactivation of DARP improves glucose homeostasis in mice
To investigate a potential role of DARP in energy metabolism in vivo, we analyzed metabolic
phenotypes of DARP-/- mice. DARP-/- mice showed body weight similar to wildtype (WT)
mice, with a little tendency to increase (Fig 2A). We then performed glucose and insulin toler-
ance test using these mice. DARP-/- mice exhibited significantly reduced blood glucose levels
after intraperitoneal administration of glucose comparing to those in WT mice, despite similar
body weight (Fig 2B and 2C). However, insulin sensitivity assessed by insulin tolerance test was
not different between DARP-/- and WTmice (Fig 2D). These results suggest that genetic loss
of DARP enhances glucose tolerance without affecting insulin sensitivity.
Loss of DARP activates AMPK in skeletal muscle
We then analyzed the expression of GLUT1 and GLUT4 in skeletal muscle. Expression of
GLUT4 in skeletal muscle was not different betweenWT and DARP-/- mice, while GLUT1
expression was reduced in DARP-/- mice comparing to that inWTmice (Fig 3A). Because
GLUT-1 expression is regulated by HIF-1α, we examined the expression levels of other HIF-1α
target genes in skeletal muscle of these mice. The expression of vascular endothelial growth fac-
tor (VEGF) and heme oxygenase-1 (Hmox1) in skeletal muscle was similar inWT and DARP-/-
mice (Fig 3B). We also analyzed expression of GLUT1 and GLUT4 in C2C12 myotubes
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transfected with either scramble or DARP siRNA. Gene-silencing of DARP did not affect the
expression of both GLUT1 and GLUT-4 in C2C12 myotubes (Fig 3C). These data suggest that
there is no direct link between DARP and HIF-1α/GLUT1. Of note, DARP-/- mice demon-
strated significantly accentuated phosphorylation of AMPK in skeletal muscle comparing to that
inWTmice (Fig 3D). In consistent with the enhanced AMPK activity, phosphorylation of ace-
tyl-CoA carboxylase (ACC) was also accentuated in skeletal muscle of DARP-/- mice (Fig 3E).
Because AMPKmediates insulin-independent glucose uptake in muscle [19–21], these results
suggest that loss of DARP might enhance glucose tolerance by activating AMPK. Therefore, we
further examined the role of DARP in AMPK activation. Gene-silencing of DARP significantly
enhanced phosphorylation of AMPK and ACC in C2C12 myotube (Fig 4A and 4B). Further-
more, we found that DARP-silencing significantly increased glucose uptake in C2C12 myotubes
(Fig 4C). Treatment with AICAR, an AMPK activator [20], enhanced phosphorylation of
AMPK and ACC in C2C12 myotubes, and the difference of their phosphorylation between con-
trol and DARP-knocked down cells disappeared after treatment with AICAR (Fig 4B). Accord-
ingly, the increase of glucose uptake by DARP-silencing was abrogated by the treatment with
AICAR (Fig 4C). In addition, glucose oxidation was enhanced by DARP-silencing in C2C12
myotubes, and this increase of glucose oxidation was also abolished by AICAR-treatment (Fig
4D and 4E). In contrast, overexpression of DARP significantly reduced the phosphorylation of
AMPK in C2C12 myoblasts comparing to the control GFP-transfected cells (Fig 4F). These data
strongly suggest that DARP negatively regulates AMPK activity in the skeletal muscle.
Enhanced AMPK activity is attributable to the better glucose
homeostasis in DARP-/- mice
We finally investigated whether AMPK activation is attributable to the enhanced glucose toler-
ance observed in DARP/- mice. Administration of AICAR abolished the better glucose toler-
ance in DARP-/- mice, indicating that enhanced AMPK activity largely accounts for the
Fig 1. Expression of DARP in mouse tissues andmyotubes. (A) Quantitative analysis for DARPmRNA expression in various mouse tissues (n = 3 each).
DARP was predominantly expressed in skeletal muscle. (B) Quantitative analysis for ANKRD2 or DARPmRNA expression in C2C12 cells during
myogenesis (n = 4 each). Expression of DARP was substantially enhanced during myogenesis, and was predominantly expressed in mature myotube.
ANKRD2 showed the less degree of up-regulation during myogenesis comparing to that of DARP.
doi:10.1371/journal.pone.0138624.g001
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enhanced glucose tolerance induced by DARP-deletion (Fig 5A). We confirmed that phos-
phorylation of AMPK and ACC in skeletal muscle was not different between WT and DARP-/-
mice after the treatment with AICAR (Fig 5B). To investigate the mechanisms responsible for
the modification of AMPK activity by DARP, we examined the expression of LKB1, a major
upstream kinase that phosphorylates AMPK [4,22]. Gene-silencing of DARP significantly
increased protein expression of LKB1 in skeletal muscle in vivo and C2C12 myotubes in vitro,
suggesting that DARP modifies AMPK activity at least partially by modulating LKB1 expres-
sion in skeletal muscle (Fig 5C and 5D). In contrast, mRNA expression of LKB1 was not
affected by DARP-silencing, indicating that DARP modifies the LKB1 expression at protein
levels but not mRNA levels (Fig 5E and 5F).
Fig 2. Inactivation of DARP improves glucose homeostasis. (A) Body weight of WT or DARP-/- mice at the indicated weeks of age. Body weight was
similar between groups, while DARP-/- mice showed minimal and inconsistent increase in body weight relative to WTmice. *P<0.05 (n = 8 each). (B)
Glucose tolerance test (ipGTT) was performed usingWT or DARP-/- mice at the age of 24 week-old. *P<0.05, **P<0.01 (n = 6 for WT and n = 7 for DARP-/-
mice). Quantification of the area-under-curve was also shown. DARP-/- mice showed better glucose tolerance comparing to that in WTmice. (C) Body weight
of WT or DARP-/- mice at the time of ipGTT. There was no significant difference of body weight betweenWT and DARP-/- mice when ipGTT was performed.
(D) Insulin tolerance test (ITT) was performed usingWT or DARP-/- mice at the age of 20 week-old (n = 7 each). Quantification of the area-under-curve was
also shown. Insulin sensitivity was similar in WT and DARP-/- mice.
doi:10.1371/journal.pone.0138624.g002
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Taken together, we unveiled a previously unknown function of DARP in the regulation of
glucose homeostasis by modulating AMPK activity, shedding light on DARP as a new thera-
peutic target for the treatment of blood glucose dysregulation in diabetic patients.
Discussion
In this study, we identified that DARP regulates glucose disposal in skeletal muscle and thus
modifies the glucose homeostasis by modulating AMPK activity. Because reduced glucose dis-
posal in skeletal muscle largely accounts for the glucose intolerance in diabetic patients [2,23],
DARP could be a novel pharmacotherapeutic target for the treatment of diabetes mellitus.
By using the PCR-based subtractive hybridization, we previously identified DARP as a
nuclear protein whose expression was differentially regulated in obese and insulin resistant
Fig 3. Loss of DARP leads to AMPK activation in skeletal muscle. (A) Quantitative analysis for GLUT1 and GLUT4 mRNA expression in skeletal muscle
of WT or DARP-/- mice. *P<0.05 (n = 6 for WTmice, n = 5 for DARP-/- mice). Expression of GLUT4 in skeletal muscle of DARP-/- mice was similar, while
GLUT1 expression in muscle of DARP-/- mice was significantly reduced comparing to those in WTmice. (B) Quantitative analysis for VEGF and Hmox1
mRNA expression in skeletal muscle of WT or DARP-/- mice. #Not significant (n = 5 each). (C) C2C12 myotubes were transfected with either negative
(scramble) or DARP siRNA (DARP-KD), and then mRNA expression of DARP, GLUT1 and GLUT4 was quantitatively analyzed. **P<0.01, #Not significant
(n = 4 each). (D) Phosphorylation of AMPK in skeletal muscle of WT or DARP-/- mice. *P<0.05 (n = 6 each). DARP-/- mice showed significantly accentuated
AMPK phosphorylation in skeletal muscle comparing to WTmice. (E) Phosphorylation of ACC in skeletal muscle of WT or DARP-/- mice. *P<0.05 (n = 6
each). DARP-/- mice showed significantly accentuated ACC phosphorylation in skeletal muscle comparing to WTmice.
doi:10.1371/journal.pone.0138624.g003
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animals [7]. DARP expression was enhanced in skeletal muscle of obese rat, and reduced
AMPK activity in skeletal muscle has been reported in obese and diabetic patients as well as in
mice with metabolic syndromes; therefore, DARP may play a causal role in the dysregulation
of AMPK under obese and/or diabetic conditions. Also, DARP expression was reduced in skel-
etal muscle by fasting, while it increased beyond the basal level after re-feeding in lean mice.
AMPK plays a vital role in the metabolic adaptation to changes in nutritional status [20,24].
Fig 4. DARP regulates AMPK activity in C2C12 cells. (A) Phosphorylation of AMPK in C2C12 myotubes transfected with either negative (scramble) or
DARP siRNA (DARP-KD) was assessed by immunoblotting. Silencing of DARP significantly enhanced the phosphorylation of AMPK. *P<0.05 (n = 3 each).
(B) Phosphorylation of AMPK and ACC in C2C12 myotubes in the presence or absence of AICAR was assessed by immunoblotting. Silencing of DARP
significantly enhanced the phosphorylation of AMPK and ACC in the absence of AICAR. Treatment with AICAR enhanced phosphorylation of AMPK and
ACC in C2C12 myotubes, and the difference of their phosphorylation between scramble and DARP-KD cells disappeared when treated with AICAR.
*P<0.05, **P<0.01, #Not significant (n = 3 each). (C) Glucose uptake in C2C12 myotubes was assessed by measuring 2-deoxyglucose uptake using an
enzymatic photometric assay. Cells were transfected with either scramble or DARP siRNA (DARP-KD), and the glucose uptake was analyzed in the
presence or absence of AICAR. Silencing of DARP significantly increased glucose uptake in C2C12 myotubes comparing to control cells. *P<0.05 (n = 5
each). Treatment with AICAR increased glucose uptake in control cells and abolished the increased glucose uptake induced by DARP-silencing. **P<0.01,
#Not significant (n = 5 each). (D) Glucose oxidation in C2C12 myotubes was assessed by 14CO2 production from
14C-D-glucose. Cells were transfected with
either scramble or DARP siRNA (DARP KD). DARP-silencing enhanced the glucose oxidation in C2C12 myotubes. **P<0.01 (n = 5 for scramble, n = 4 for
DARP KD). (E) Treatment with AICAR abrogated the increase in glucose oxidation induced by DARP-silencing (n = 3 each). (F) C2C12 myoblasts were
infected with retroviruses carrying GFP (GFP) or DARP (DARPOE) gene, and then phosphorylation of AMPK was assessed by immunoblotting.
Overexpression of DARP significantly reduced the phosphorylation of AMPK. **P<0.01 (n = 3 each).
doi:10.1371/journal.pone.0138624.g004
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The AMPK system is regulated by AMP-to-ATP ratio through allosteric and non-allosteric
phosphorylation of a key threonine residue, and thus functions as a master energy sensor gov-
erning the adaptive metabolic changes to fasting [24,25]. Fasting activates AMPK, which inhib-
its anabolic pathways and enhances catabolic processes, to restore ATP levels [24]. Because
DARP likely inhibits AMPK activity, fasting-induced decline in DARP expression may contrib-
ute to the efficient activation of AMPK system during fasting. Also, rebound increase of DARP
expression might be helpful to sufficiently inactivate AMPK system after re-feeding. Therefore,
DARP might be involved in the metabolic adaptive responses to the changes in nutritional sta-
tus as well through the fine-tuning of AMPK activity in skeletal muscle.
There are two other members in MARP family; CARP and ANKRD2 [8,9]. Despite the
striking expression pattern in the heart and skeletal muscle, and possible association with dis-
eases such as cardiac hypertrophy, dilated cardiomyopathy, skeletal muscle myopathy and
Fig 5. Enhanced AMPK activity is attributable to the better glucose homeostasis in DARP-/- mice. (A) Glucose tolerance was analyzed in WT or
DARP-/- mice treated with AICAR at the age of 24 weeks old (n = 6 for WTmice, n = 7 for DARP-/- mice). Administration of AICAR abolished the better
glucose tolerance in DARP-/- mice. (B) Phosphorylation of AMPK and ACC in skeletal muscle of WT or DARP-/- mice treated with AICAR was assessed by
immunoblotting. #Not significant (n = 7 each). (C) LKB1 expression in skeletal muscle was assessed by immunoblotting. Protein expression of LKB1
increased in skeletal muscle of DARP-/- mice comparing to that in WTmice. *P<0.05 (n = 4 each). (D) LKB1 expression in C2C12 myotubes transfected with
either negative (scramble) or DARP siRNA (DARP-KD) was assessed by immunoblotting. Protein expression of LKB1 increased in DARP-KDmyotubes
comparing to that in scramble control cells. **P<0.01 (n = 3 each). (E) Quantitative analysis for LKB1 mRNA expression in skeletal muscle of WT or DARP-/-
mice (n = 6 for WT and n = 5 for DARP-/-). LKB1 expression in skeletal muscle was not significantly different betweenWT and DARP-/- mice. (F) Quantitative
analysis for LKB1 mRNA expression in C2C12 myotubes transfected with either negative (scramble) or DARP siRNA (DARP-KD). LKB1 expression in
myotubes was not significantly different between scramble and DARP-KD cells (n = 4 each).
doi:10.1371/journal.pone.0138624.g005
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muscular dystrophy, physiological roles of CARP and ANKRD2 remain unclear [12]. CARP
was initially identified as a cytokine-inducible gene in endothelial cells, and later revealed to be
a downstream of the homeobox gene Nkx2.5 and regulate the expression of cardiac genes
[12,26]. ANKRD2 has been identified as a mechanical stretch-responsible gene in skeletal mus-
cle, and its expression was differentially regulated in response to exercise, eccentric contraction
and denervation [27]. Recently, it has been reported that mice with triple knockout for CARP,
ANKRD2 and DARP are viable and fertile, and they showed no macroscopic as well as micro-
scopic abnormalities in the heart and skeletal muscle [9,12]. Detailed analysis revealed that loss
of all MARP family members caused a greater degree of torque loss after a bout of eccentric
contraction in muscles, but no significant difference in cardiac function and hypertrophy was
detected in these mice [9,12]. Studies using gene knockout mice are needed to elucidate
whether CARP and ANKRD2 are also involved in the glucose homeostasis and/or energy
metabolism in the heart and skeletal muscle.
In summary, we have identified that DARP modifies glucose homeostasis by modulating
AMPK activity in skeletal muscle. Also, DARP may play a role in adaptive metabolic changes
to nutritional variation through a fine-tuning of AMPK activity. However, detailed molecular
mechanisms underlying the DARP-mediated modification of AMPK activity remain to be elu-
cidated although LKB1 is likely involved in these mechanisms. Also, we used DARP-null mice
in this study, but muscle-specific knockout of DARP is needed to clearly show the DARP func-
tion in skeletal muscle. Further analyses, especially for the pathway in AMPK phosphorylation
and dephosphorylation are required to identify molecular mechanisms how DARP modifies
AMPK activity and systemic glucose homeostasis.
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